CN117016786A - Soybean lecithin tablet with blood lipid reducing function and preparation method thereof - Google Patents
Soybean lecithin tablet with blood lipid reducing function and preparation method thereof Download PDFInfo
- Publication number
- CN117016786A CN117016786A CN202310889789.XA CN202310889789A CN117016786A CN 117016786 A CN117016786 A CN 117016786A CN 202310889789 A CN202310889789 A CN 202310889789A CN 117016786 A CN117016786 A CN 117016786A
- Authority
- CN
- China
- Prior art keywords
- soybean lecithin
- tablet
- blood lipid
- vitamin
- moisture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 title claims abstract description 164
- 229940083466 soybean lecithin Drugs 0.000 title claims abstract description 164
- 210000004369 blood Anatomy 0.000 title claims abstract description 125
- 239000008280 blood Substances 0.000 title claims abstract description 125
- 230000001603 reducing effect Effects 0.000 title claims abstract description 99
- 150000002632 lipids Chemical class 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 126
- 239000000843 powder Substances 0.000 claims abstract description 64
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 63
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 63
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 63
- 229940046009 vitamin E Drugs 0.000 claims abstract description 63
- 239000011709 vitamin E Substances 0.000 claims abstract description 63
- 229940109850 royal jelly Drugs 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 33
- 239000000212 ceratonia siliqua l. fruit extract Substances 0.000 claims abstract description 29
- 239000003826 tablet Substances 0.000 claims description 155
- 235000003599 food sweetener Nutrition 0.000 claims description 53
- 239000003765 sweetening agent Substances 0.000 claims description 53
- 239000002994 raw material Substances 0.000 claims description 47
- 239000000314 lubricant Substances 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 42
- 239000000945 filler Substances 0.000 claims description 41
- 239000000853 adhesive Substances 0.000 claims description 34
- 230000001070 adhesive effect Effects 0.000 claims description 34
- 240000008886 Ceratonia siliqua Species 0.000 claims description 26
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 26
- 238000007873 sieving Methods 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000011230 binding agent Substances 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- 235000009496 Juglans regia Nutrition 0.000 claims description 13
- 239000001506 calcium phosphate Substances 0.000 claims description 13
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 13
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 13
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 13
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 13
- 235000020234 walnut Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 229920002261 Corn starch Polymers 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 229940089206 anhydrous dextrose Drugs 0.000 claims description 9
- 239000008120 corn starch Substances 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 239000007910 chewable tablet Substances 0.000 claims description 7
- 239000000686 essence Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 5
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 5
- 229940071440 soy protein isolate Drugs 0.000 claims description 5
- 239000008347 soybean phospholipid Substances 0.000 claims description 5
- 244000144725 Amygdalus communis Species 0.000 claims description 4
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 102000014171 Milk Proteins Human genes 0.000 claims description 4
- 108010011756 Milk Proteins Proteins 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 235000020224 almond Nutrition 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 235000021239 milk protein Nutrition 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229910021487 silica fume Inorganic materials 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000011361 granulated particle Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 240000007049 Juglans regia Species 0.000 claims 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 16
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 13
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 13
- 230000002195 synergetic effect Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 6
- 230000006866 deterioration Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 24
- 239000000796 flavoring agent Substances 0.000 description 17
- 235000019634 flavors Nutrition 0.000 description 17
- 235000019640 taste Nutrition 0.000 description 17
- 230000003647 oxidation Effects 0.000 description 12
- 238000007254 oxidation reaction Methods 0.000 description 12
- 241000758789 Juglans Species 0.000 description 11
- 230000004888 barrier function Effects 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 230000002708 enhancing effect Effects 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- -1 moisture barriers Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 229940083690 soybean lecithin chewable tablet Drugs 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000004067 bulking agent Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 208000026758 coronary atherosclerosis Diseases 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000006241 metabolic reaction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The application belongs to the technical field of food health care, and particularly relates to a soybean lecithin tablet with a blood lipid reducing function and a preparation method thereof. The soybean lecithin tablet with the blood lipid reducing function comprises functional components and auxiliary materials, wherein the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob bean extract. The soybean lecithin tablet with the blood lipid reducing function can effectively reduce blood lipid and prevent cardiovascular and cerebrovascular diseases and other diseases through the synergistic effect of the soybean lecithin, the vitamin E, the royal jelly powder and the carob bean extract. And the product is a tablet, and compared with a capsule, the tablet has the advantages of accurate dosage, uniform content of main medicine, stable quality, small volume, compactness, less influence by factors such as external air, light, moisture and the like, difficult deterioration, simple use, convenient carrying, and convenient transportation, storage and use.
Description
Technical Field
The application belongs to the technical field of food health care, and particularly relates to a soybean lecithin tablet with a blood lipid reducing function and a preparation method thereof.
Background
Hyperlipidemia is a common disease caused by abnormal lipid metabolism of human body, and mainly refers to excessive or low levels of total cholesterol, triglyceride and low density lipoprotein in serum. The hyperlipidemia has no obvious clinical symptoms in the early stage, and the damage to the body is hidden and progressive and systemic. Because hyperlipidemia accelerates atherosclerosis, many diseases such as cardiovascular and cerebrovascular diseases, kidney diseases, liver diseases, etc. are caused once the artery is blocked. Among them, cardiovascular and cerebrovascular diseases are the main cause of death for middle-aged and elderly people, and are the first killer threatening human health. Therefore, the current hyperlipidemia seriously threatens the health of human beings, and along with the continuous improvement of the living standard of people in China, the development of urbanization and industrialization changes the eating habits of people, the physical activity is gradually reduced, and the hyperlipidemia population is further enlarged. Moreover, with the development of economy and science, the requirements of people on life quality are higher and higher, the importance of "preventing and curing" is gradually realized, the importance of health is reached to the unprecedented degree, and the related research of medicines and health care foods is one focus of common social attention.
Soybean lecithin is a socially accepted health food raw material with the function of assisting in reducing blood lipid, and related products in the market are mostly soft capsules at present, but are easily deteriorated due to the influence of factors such as external air, light, moisture and the like.
Disclosure of Invention
The application aims to provide a soybean lecithin tablet with a blood lipid reducing function and a preparation method thereof, and aims to solve the problem that the existing soybean lecithin is mostly soft capsules in health-care foods with the blood lipid reducing function and is easily deteriorated due to the influence of factors such as air, light rays and moisture.
In order to achieve the purposes of the application, the technical scheme adopted by the application is as follows:
in a first aspect, the application provides a soybean lecithin tablet with a blood lipid reducing function, which comprises functional components and auxiliary materials, wherein the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob extract.
In some possible implementations, the tablet includes an active ingredient and an adjuvant, wherein the active ingredient includes soybean lecithin, vitamin E, royal jelly powder, and carob extract.
In some possible implementations, the adjuvants include sweeteners, moisture barriers, binders, fillers, fragrances, glidants, and lubricants.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 20-40% of soybean lecithin, 1-5% of vitamin E, 1-10% of royal jelly powder, 1-10% of carob bean extract, 20-40% of sweetener, 10-30% of moisture-proof agent, 5-20% of adhesive, 1-10% of filler, 0.5-1.5% of essence, 1-2% of glidant and 0.5-1.5% of lubricant.
In some possible implementations, the sweetener includes at least one of anhydrous dextrose, sucrose, mannitol.
In some possible implementations, the moisture barrier includes at least one of tricalcium phosphate, anhydrous dibasic calcium phosphate.
In some possible implementations, the binder includes at least one of corn starch, modified starch, maltodextrin.
In some possible implementations, the bulking agent includes at least one of soy protein isolate, soy flour, milk protein concentrate.
In some possible implementations, the flavor includes at least one of walnut powder flavor, almond flavor, and walnut flavor.
In some possible implementations, the glidant includes at least one of silicon dioxide, micro-silica gel, polyethylene glycol.
In some possible implementations, the lubricant includes at least one of magnesium stearate, stearic acid, talc.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 30% of soybean lecithin, 3% of vitamin E, 5% of royal jelly powder, 3% of carob extract, 24% of sweetener, 16% of moisture-proof agent, 10% of adhesive, 5% of filler, 1% of essence, 2% of glidant and 1% of lubricant.
In some possible implementations, 20% soy lecithin, 2% vitamin E, 4% royal jelly powder, 5% carob extract, 30% sweetener, 20% moisture barrier, 11.9% binder, 4% filler, 0.8% flavor, 1.5% glidant, and 0.8% lubricant.
In some possible implementations, the soy lecithin 40%, vitamin E1%, royal jelly powder 2%, carob extract 3%, sweetener 28%, moisture barrier 15%, binder 6%, bulking agent 3%, fragrance 0.5%, glidant 1% and lubricant 0.5%.
In some possible implementations, the soy lecithin is 25%, the vitamin E4%, the royal jelly powder is 8%, the carob extract is 8%, the sweetener is 20%, the moisture barrier is 12%, the binder is 12.3%, the filler is 6%, the flavor is 1.5%, the glidant is 2%, and the lubricant is 1.2%.
In some possible implementations, the soybean lecithin tablet with the blood lipid-lowering function comprises soybean lecithin chewable tablets with the blood lipid-lowering function, and each tablet weighs 0.8 g-1.5 g.
In a second aspect, the application provides a preparation method of a soybean lecithin tablet with a blood lipid reducing function, comprising the following steps:
obtaining raw material components, wherein the raw material components comprise functional components and auxiliary materials, and the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob bean extract;
and mixing the raw material components, granulating, and tabletting to obtain the soybean lecithin tablet with the blood lipid reducing function.
In some possible implementations, the raw material components have a total mass of 100%, and include the following components in percentage by mass: 20-40% of soybean lecithin, 1-5% of vitamin E, 1-10% of royal jelly powder, 1-10% of carob bean extract, 20-40% of sweetener, 10-30% of moisture-proof agent, 5-20% of adhesive, 1-10% of filler, 0.5-1.5% of essence, 1-2% of glidant and 0.5-1.5% of lubricant.
In some possible implementations, the step of mixing granulation includes: wet granulating the sweetener, the moisture-proof agent and the adhesive with water according to the formula amount, drying, sieving, and mixing with the soybean lecithin, the vitamin E, the royal jelly powder, the carob bean extract, the filler, the essence, the glidant and the lubricant according to the formula amount for granulation.
In some possible implementations, the mass ratio of the total mass of the sweetener, the moisture barrier, and the binder to the mass of water is 1: (0.2-0.3).
In some possible implementations, the step of drying and sieving includes: and drying the wet granulated particles at the temperature of 50-65 ℃ until the moisture content of the particles is not higher than 2.5wt%, and sieving the particles with a 20-mesh sieve.
In some possible implementations, after the raw material component is obtained, a treatment step of passing the soybean lecithin through a 20-mesh sieve and passing the other raw material component through a 40-mesh sieve is further included.
The soybean lecithin tablet with the blood lipid reducing function provided by the first aspect of the application comprises functional components and auxiliary materials. The main components of soybean lecithin include phosphatidylcholine, cephalin (phosphatidylethanolamine), phosphatidylinositol, phosphatidylserine, etc. The soybean lecithin can emulsify and decompose oil and fat, and can emulsify cholesterol and fat attached to blood vessel wall into microparticles, so that the microparticles can be dissolved in blood and transported back to liver for metabolism. Has effects of softening blood vessel, improving serum lipid, and scavenging peroxide, and reducing cholesterol and fat content in blood, thereby reducing blood viscosity, promoting blood circulation, and reducing residence time of fat in blood vessel. The vitamin E can accelerate the dissolution and decomposition of lipid in blood in pharmacology, promote the discharge of cholesterol, and up-regulate or down-regulate related genes of lipid intake or arteriosclerosis, so that the cholesterol level in blood plasma and the concentration of low-density lipoprotein in blood plasma can be reduced to a certain extent, a certain blood lipid reducing effect can be achieved, and coronary atherosclerosis can be prevented or treated. In addition, vitamin E is fat-soluble vitamin, participates in metabolic reaction of organisms, and has the effects of resisting peroxidation of free radicals, delaying aging, protecting skin, enhancing ovarian function and the like. Therefore, the vitamin E can prevent the oxidation of the soybean lecithin and promote the absorption and utilization of the soybean lecithin, so that the soybean lecithin and the vitamin E have the mutual synergistic and promoting effects. The main components of the royal jelly are amino acid and protein, are rich in phospholipid components, have the functions of resisting oxidation, enhancing immunity and purifying blood, can reduce blood fat, and can play roles of resisting oxidation and enhancing immunity together with soybean lecithin when being used together, thus having a synergistic effect. The saponin component in the carob extract has good lipid-lowering effect, can effectively lower the low density lipoprotein cholesterol in blood, and has positive effects in preventing atherosclerosis and cardiovascular diseases. Through the synergistic effect of soybean lecithin, vitamin E, royal jelly powder and carob bean extract, the blood fat can be effectively reduced, and cardiovascular and cerebrovascular diseases and the like can be prevented. And the product is a tablet, and compared with a capsule, the tablet has the advantages of accurate dosage, uniform content of main medicine, stable quality, small volume and compactness, is less influenced by factors such as external air, light, moisture and the like, is not easy to deteriorate, and is convenient to transport, store and use.
According to the preparation method of the soybean lecithin tablet with the blood lipid reducing function, provided by the second aspect of the application, after the raw material components are obtained, mixed granulation is carried out, and then tabletting is carried out, so that the soybean lecithin tablet with the blood lipid reducing function can be obtained. The preparation process is simple, and the dosage, shape, size and the like of the tablet can be accurately and flexibly regulated and controlled. Can be prepared into small and compact soybean lecithin tablets with the function of reducing blood fat, is less affected by factors such as external air, light, moisture and the like, is not easy to deteriorate, and has good quality and performance stability. The prepared soybean lecithin tablet with the blood lipid reducing function contains functional components such as soybean lecithin, vitamin E, royal jelly powder, carob bean extract and the like, and can effectively reduce blood lipid and prevent cardiovascular and cerebrovascular diseases and the like through the synergistic effect of the soybean lecithin, the vitamin E, the royal jelly powder and the carob bean extract.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings that are needed in the embodiments or the description of the prior art will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and that other drawings can be obtained according to these drawings without inventive effort for a person skilled in the art.
Fig. 1 is a schematic flow chart of a preparation method of a soybean lecithin tablet with a blood lipid reducing function provided by the embodiment of the application.
Detailed Description
In order to make the technical problems, technical schemes and beneficial effects to be solved more clear, the application is further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the application.
In the present application, the term "and/or" describes an association relationship of an association object, which means that three relationships may exist, for example, a and/or B may mean: a alone, a and B together, and B alone. Wherein A, B may be singular or plural. The character "/" generally indicates that the context-dependent object is an "or" relationship.
In the present application, "at least one" means one or more, and "a plurality" means two or more. "at least one of" or the like means any combination of these items, including any combination of single item(s) or plural items(s). For example, "at least one (individual) of a, b, or c," or "at least one (individual) of a, b, and c" may each represent: a, b, c, a-b (i.e., a and b), a-c, b-c, or a-b-c, wherein a, b, c may be single or multiple, respectively.
It should be understood that, in various embodiments of the present application, the sequence number of each process described above does not mean that the execution sequence of some or all of the steps may be executed in parallel or executed sequentially, and the execution sequence of each process should be determined by its functions and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
The terminology used in the embodiments of the application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. As used in this application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
The weights of the relevant components mentioned in the embodiments of the present application may refer not only to the specific contents of the respective components but also to the proportional relationship between the weights of the respective components, and thus, it is within the scope of the disclosure of the embodiments of the present application as long as the contents of the relevant components are scaled up or down according to the embodiments of the present application. Specifically, the mass described in the examples of the present application may be a mass unit known in the chemical industry such as μ g, mg, g, kg.
The terms "first" and "second" are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated for distinguishing between objects such as substances from each other. For example, a first XX may also be referred to as a second XX, and similarly, a second XX may also be referred to as a first XX, without departing from the scope of embodiments of the application. Thus, a feature defining "a first" or "a second" may explicitly or implicitly include one or more such feature.
The first aspect of the embodiment of the application provides a soybean lecithin tablet with a blood lipid reducing function, which comprises functional components and auxiliary materials, wherein the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob extract.
The soybean lecithin tablet with the blood lipid reducing function provided by the first aspect of the embodiment of the application comprises functional components and auxiliary materials. The main components of soybean lecithin include phosphatidylcholine, cephalin (phosphatidylethanolamine), phosphatidylinositol, phosphatidylserine, etc. The soybean lecithin can emulsify and decompose oil and fat, and can emulsify cholesterol and fat attached to blood vessel wall into microparticles, so that the microparticles can be dissolved in blood and transported back to liver for metabolism. Has effects of softening blood vessel, improving serum lipid, and scavenging peroxide, and reducing cholesterol and fat content in blood, thereby reducing blood viscosity, promoting blood circulation, and reducing residence time of fat in blood vessel. The vitamin E can accelerate the dissolution and decomposition of lipid in blood in pharmacology, promote the discharge of cholesterol, and up-regulate or down-regulate related genes of lipid intake or arteriosclerosis, so that the cholesterol level in blood plasma and the concentration of low-density lipoprotein in blood plasma can be reduced to a certain extent, a certain blood lipid reducing effect can be achieved, and coronary atherosclerosis can be prevented or treated. In addition, vitamin E is fat-soluble vitamin, participates in metabolic reaction of organisms, and has the effects of resisting peroxidation of free radicals, delaying aging, protecting skin, enhancing ovarian function and the like. Therefore, the vitamin E can prevent the oxidation of the soybean lecithin and promote the absorption and utilization of the soybean lecithin, so that the soybean lecithin and the vitamin E have the mutual synergistic and promoting effects. The main components of the royal jelly are amino acid and protein, are rich in phospholipid components, have the functions of resisting oxidation, enhancing immunity and purifying blood, can reduce blood fat, and can play roles of resisting oxidation and enhancing immunity together with soybean lecithin when being used together, thus having a synergistic effect. The saponin component in the carob extract has good lipid-lowering effect, can effectively lower the low density lipoprotein cholesterol in blood, and has positive effects in preventing atherosclerosis and cardiovascular diseases. At the same time, it can also reduce insulin resistance, improve blood sugar, raise glycosylated hemoglobin, reduce testosterone male hormone, reduce triglyceride in blood and blood pressure, and increase sex hormone binding globulin, etc. Through the synergistic effect of soybean lecithin, vitamin E, royal jelly powder and carob bean extract, the blood fat can be effectively reduced, and cardiovascular and cerebrovascular diseases and the like can be prevented. And the product is a tablet, and compared with a capsule, the tablet has the advantages of accurate dosage, uniform content of main medicine, stable quality, small volume, compactness, less influence by factors such as external air, light, moisture and the like, difficult deterioration, simple use, convenient carrying, and convenient transportation, storage and use.
In some possible implementations, the adjuvants include sweeteners, moisture barriers, binders, fillers, fragrances, glidants, and lubricants. Wherein, the sweetener is used for adjusting the taste of the soybean lecithin tablet with the mouth having the function of reducing blood fat; the dampproof agent is used for preventing the soybean lecithin tablet with the blood lipid reducing function from absorbing moisture; the binder participates in granulating; the filling agent is used for adjusting the tablet weight of the soybean lecithin tablet with the blood fat reducing function; the essence is used for improving the taste of the soybean lecithin tablet with the blood lipid reducing function; the glidant is used for improving the fluidity of the material; the lubricant is used for demolding. In the soybean lecithin tablet with the blood lipid reducing function, the soybean lecithin tablet with the blood lipid reducing function has the characteristics of good stability, uniform main medicine content, stable quality, small and compact volume, difficult influence by factors such as external air, light rays, moisture and the like, difficult deterioration and the like through the synergistic and comprehensive effects of the functional components and the auxiliary materials such as the sweetener, the moisture-proof agent, the adhesive, the filling agent, the essence, the glidant and the lubricant. Improving the convenience of transportation, storage and use of the soybean lecithin tablet with the blood lipid reducing function.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 20-40% of soybean lecithin, 1-5% of vitamin E, 1-10% of royal jelly powder, 1-10% of carob bean extract, 20-40% of sweetener, 10-30% of moisture-proof agent, 5-20% of adhesive, 1-10% of filler, 0.5-1.5% of essence, 1-2% of glidant and 0.5-1.5% of lubricant. In the soybean lecithin tablet with the blood lipid reducing function, soybean lecithin, vitamin E, royal jelly powder and carob bean extract are used as effective components, and the content of each effective component fully ensures the effects of the tablet on reducing blood lipid and preventing cardiovascular and cerebrovascular diseases. Wherein, the dosage of the soybean lecithin and the royal jelly powder is relatively low, thus effectively ensuring the tabletting effect of the soybean lecithin tablet with the blood fat reducing function. In addition, the vitamin E plays roles of antioxidation and synergism, solves the problems of easy oxidation and poor stability of the functional components, and ensures the stability of the soybean lecithin tablet with the blood fat reducing function. The dosage of the sweetener can effectively regulate the taste of the soybean lecithin tablet with the blood fat reducing function; the dosage of the moisture-proof agent can effectively prevent the tablets from absorbing moisture; the dosage of the adhesive can effectively participate in granulation, so that the granulating effect is ensured; the dosage of the filler can effectively regulate the tablet weight, so that the soybean lecithin tablet with the blood fat reducing function reaches the required size, and the stability of the tablet is improved; the dosage of the essence can effectively improve the taste of the soybean lecithin tablet with the blood fat reducing function; the consumption of the glidant can effectively improve the fluidity of the materials; the amount of lubricant is such that the tablet can be effectively de-molded.
In some possible implementations, the sweetener includes at least one of anhydrous dextrose, sucrose, mannitol; the sweetener can reduce the bitter taste of the soybean lecithin tablet with the blood lipid reducing function, so that the tablet has better taste. In some specific embodiments, the sweetener adopts anhydrous glucose, so that the taste correction effect is good, the bitter taste of the product can be reduced, the tablet has better taste, and the anhydrous is beneficial to improving the stability of the soybean lecithin tablet with the blood lipid reducing function.
In some possible implementations, the moisture barrier includes at least one of tricalcium phosphate, anhydrous dibasic calcium phosphate; these substances can all play a role in preventing the product from absorbing moisture. In some specific embodiments, the moisture-proof agent adopts tricalcium phosphate, has good moisture-proof effect, and can prevent the mutual adhesion of tablets caused by moisture absorption of the product and oxidation deterioration. In addition, tricalcium phosphate is a safe nutrition enhancer, is beneficial to enhancing calcium intake, and can be used for preventing or treating calcium deficiency symptoms. At the same time, tricalcium phosphate can also be used as an anticaking agent, a PH value regulator, a buffering agent and the like.
In some possible implementations, the binder includes at least one of corn starch, modified starch, maltodextrin; the components can play a role in binding in the granulating process, so that the binding stability of each component in the soybean lecithin tablet with the blood fat reducing function is improved. In some embodiments, the adhesive is corn starch, which provides good adhesion.
In some possible implementations, the bulking agent includes at least one of soy protein isolate, soy flour, milk protein concentrate; the substances can play a good filling role in the soybean lecithin tablet with the blood lipid reducing function, flexibly adjust the tablet weight of the soybean lecithin tablet with the blood lipid reducing function and are beneficial to the stable excipient of the tablet. In some embodiments, the filler is soy protein isolate, which has a highest in vivo digestion and absorption biological value and a digestibility of 93% -97% compared to other proteins. And can effectively supplement immune cells in vivo, produce antibodies against bacteria and infection for the immune system, and enhance the disease resistance of organisms. Helping the body to make new tissue to replace the damaged tissue, delivering various nutrients to the cells, and making enzymes in the body to help convert food into energy.
In some possible implementations, the flavor includes at least one of walnut powder flavor, almond flavor, walnut flavor; the flavors can effectively regulate the taste of the tablet. In some embodiments, the flavor is walnut powder flavor.
In some possible implementations, the glidant includes at least one of silicon dioxide, micro-silica gel, polyethylene glycol; the substances can improve the fluidity of materials and the tabletting performance. In some specific embodiments, the glidant adopts silicon dioxide, has high purity and good fluidity, is an excellent flow promoter in the tablet preparation process, can greatly improve the fluidity of particles, improves the bulk density, increases the hardness of the prepared tablet, shortens the disintegration time, and further improves the dissolution speed of the medicine.
In some possible implementations, the lubricant includes at least one of magnesium stearate, stearic acid, talc, which all facilitate tablet release and enhance the tableting effect of the soy lecithin tablet with hypolipidemic function. In some embodiments, the lubricant is magnesium stearate, which has strong flowability and compressibility.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 30% of soybean lecithin, 3% of vitamin E, 5% of royal jelly powder, 3% of carob extract, 24% of sweetener, 16% of moisture-proof agent, 10% of adhesive, 5% of filler, 1% of essence, 2% of glidant and 1% of lubricant.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 20% of soybean lecithin, 2% of vitamin E, 4% of royal jelly powder, 5% of carob extract, 30% of sweetener, 20% of moisture-proof agent, 11.9% of adhesive, 4% of filler, 0.8% of essence, 1.5% of glidant and 0.8% of lubricant.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 40% of soybean lecithin, 1% of vitamin E, 2% of royal jelly powder, 3% of carob extract, 28% of sweetener, 15% of moisture-proof agent, 6% of adhesive, 3% of filler, 0.5% of essence, 1% of glidant and 0.5% of lubricant.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 25% of soybean lecithin, 4% of vitamin E, 8% of royal jelly powder, 8% of carob extract, 20% of sweetener, 12% of moisture-proof agent, 12.3% of adhesive, 6% of filler, 1.5% of essence, 2% of glidant and 1.2% of lubricant.
The soybean lecithin tablet with the blood lipid reducing function prepared by the formula of the embodiment of the application can effectively reduce blood lipid and prevent cardiovascular and cerebrovascular diseases. And the product is a tablet, and compared with a capsule, the tablet has the advantages of accurate dosage, uniform content of main medicine, stable quality, small volume and compactness, is less influenced by factors such as external air, light, moisture and the like, is not easy to deteriorate, and is convenient to transport, store and use.
In some possible implementations, the soybean lecithin tablet with the blood lipid reducing function comprises soybean lecithin chewable tablets with the blood lipid reducing function, and each tablet weighs 0.8 g-1.5 g, and is orally taken and chewed for swallowing when in use. The soybean lecithin chewable tablet with the blood lipid reducing function is convenient to carry and simple to use, and has the effects of reducing blood lipid, preventing cardiovascular and cerebrovascular diseases and the like.
In a second aspect, as shown in fig. 1, an embodiment of the present application provides a method for preparing a soybean lecithin tablet with a blood lipid-lowering function, comprising the following steps:
s10, obtaining raw material components, wherein the raw material components comprise functional components and auxiliary materials, and the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob bean extract;
s20, mixing the raw material components, granulating, and tabletting to obtain the soybean lecithin tablet with the blood lipid reducing function.
According to the preparation method of the soybean lecithin tablet with the blood lipid reducing function, provided by the second aspect of the embodiment of the application, after the raw material components are obtained, mixed granulation is carried out, and then tabletting is carried out, so that the soybean lecithin tablet with the blood lipid reducing function can be obtained. The preparation process is simple, and the dosage, shape, size and the like of the tablet can be accurately and flexibly regulated and controlled. Can be prepared into small and compact soybean lecithin tablets with the function of reducing blood fat, is less affected by factors such as external air, light, moisture and the like, is not easy to deteriorate, and has good quality and performance stability. The prepared soybean lecithin tablet with the blood lipid reducing function contains functional components such as soybean lecithin, vitamin E, royal jelly powder, carob bean extract and the like, and can effectively reduce blood lipid and prevent cardiovascular and cerebrovascular diseases and the like through the synergistic effect of the soybean lecithin, the vitamin E, the royal jelly powder and the carob bean extract.
In some embodiments, in step S10, the raw material components include an effective component and an auxiliary material, wherein the effective component includes soybean lecithin, vitamin E, royal jelly powder and carob bean extract; the auxiliary materials comprise sweetener, moisture-proof agent, adhesive, filler, essence, glidant and lubricant. The main components of soybean lecithin include phosphatidylcholine, cephalin (phosphatidylethanolamine), phosphatidylinositol, phosphatidylserine, etc. The soybean lecithin can emulsify and decompose oil and fat, and can emulsify cholesterol and fat attached to blood vessel wall into microparticles, so that the microparticles can be dissolved in blood and transported back to liver for metabolism. Has effects of softening blood vessel, improving serum lipid, and scavenging peroxide, and reducing cholesterol and fat content in blood, thereby reducing blood viscosity, promoting blood circulation, and reducing residence time of fat in blood vessel. The vitamin E can accelerate the dissolution and decomposition of lipid in blood in pharmacology, promote the discharge of cholesterol, and up-regulate or down-regulate related genes of lipid intake or arteriosclerosis, so that the cholesterol level in blood plasma and the concentration of low-density lipoprotein in blood plasma can be reduced to a certain extent, a certain blood lipid reducing effect can be achieved, and coronary atherosclerosis can be prevented or treated. In addition, vitamin E is fat-soluble vitamin, participates in metabolic reaction of organisms, and has the effects of resisting peroxidation of free radicals, delaying aging, protecting skin, enhancing ovarian function and the like. Therefore, the vitamin E can prevent the oxidation of the soybean lecithin and promote the absorption and utilization of the soybean lecithin, so that the soybean lecithin and the vitamin E have the mutual synergistic and promoting effects. The main components of the royal jelly are amino acid and protein, are rich in phospholipid components, have the functions of resisting oxidation, enhancing immunity and purifying blood, can reduce blood fat, and can play roles of resisting oxidation and enhancing immunity together with soybean lecithin when being used together, thus having a synergistic effect. The saponin component in the carob extract has good lipid-lowering effect, can effectively lower the low density lipoprotein cholesterol in blood, and has positive effects in preventing atherosclerosis and cardiovascular diseases. In the auxiliary materials, the sweetener is used for adjusting the taste of the soybean lecithin tablet with the mouth having the function of reducing blood fat; the dampproof agent is used for preventing the soybean lecithin tablet with the blood lipid reducing function from absorbing moisture; the binder participates in granulating; the filling agent is used for adjusting the tablet weight of the soybean lecithin tablet with the blood fat reducing function; the essence is used for improving the taste of the soybean lecithin tablet with the blood lipid reducing function; the glidant is used for improving the fluidity of the material; the lubricant is used for demolding. In the soybean lecithin tablet with the blood lipid reducing function, the soybean lecithin tablet with the blood lipid reducing function has the characteristics of good stability, uniform main medicine content, stable quality, small and compact volume, difficult influence by factors such as external air, light rays, moisture and the like, difficult deterioration and the like through the synergistic and comprehensive effects of the functional components and the auxiliary materials such as the sweetener, the moisture-proof agent, the adhesive, the filling agent, the essence, the glidant and the lubricant. Improving the convenience of transportation, storage and use of the soybean lecithin tablet with the blood lipid reducing function.
In some possible implementations, the total mass of the raw material components is 100%, including the following components in percentage by mass: 20-40% of soybean lecithin, 1-5% of vitamin E, 1-10% of royal jelly powder, 1-10% of carob bean extract, 20-40% of sweetener, 10-30% of moisture-proof agent, 5-20% of adhesive, 1-10% of filler, 0.5-1.5% of essence, 1-2% of glidant and 0.5-1.5% of lubricant. In the soybean lecithin tablet with the blood lipid reducing function, soybean lecithin, vitamin E, royal jelly powder and carob bean extract are used as effective components, and the content of each effective component fully ensures the effects of the tablet on reducing blood lipid and preventing cardiovascular and cerebrovascular diseases. Wherein, the dosage of the soybean lecithin and the royal jelly powder is relatively low, thus effectively ensuring the tabletting effect of the soybean lecithin tablet with the blood fat reducing function. In addition, the vitamin E plays roles of antioxidation and synergism, solves the problems of easy oxidation and poor stability of the functional components, and ensures the stability of the soybean lecithin tablet with the blood fat reducing function. The dosage of the sweetener can effectively regulate the taste of the soybean lecithin tablet with the blood fat reducing function; the dosage of the moisture-proof agent can effectively prevent the tablets from absorbing moisture; the dosage of the adhesive can effectively participate in granulation, so that the granulating effect is ensured; the dosage of the filler can effectively regulate the tablet weight, so that the soybean lecithin tablet with the blood fat reducing function reaches the required size, and the stability of the tablet is improved; the dosage of the essence can effectively improve the taste of the soybean lecithin tablet with the blood fat reducing function; the consumption of the glidant can effectively improve the fluidity of the materials; the amount of lubricant is such that the tablet can be effectively de-molded.
In some possible implementations, the sweetener includes at least one of anhydrous dextrose, sucrose, mannitol.
In some possible implementations, the moisture barrier includes at least one of tricalcium phosphate, anhydrous dibasic calcium phosphate.
In some possible implementations, the binder includes at least one of corn starch, modified starch, maltodextrin.
In some possible implementations, the bulking agent includes at least one of soy protein isolate, soy flour, milk protein concentrate.
In some possible implementations, the flavor includes at least one of walnut powder flavor, almond flavor, and walnut flavor.
In some possible implementations, the glidant includes at least one of silicon dioxide, micro-silica gel, polyethylene glycol.
In some possible implementations, the lubricant includes at least one of magnesium stearate, stearic acid, talc.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 30% of soybean lecithin, 3% of vitamin E, 5% of royal jelly powder, 3% of carob extract, 24% of sweetener, 16% of moisture-proof agent, 10% of adhesive, 5% of filler, 1% of essence, 2% of glidant and 1% of lubricant.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 20% of soybean lecithin, 2% of vitamin E, 4% of royal jelly powder, 5% of carob extract, 30% of sweetener, 20% of moisture-proof agent, 11.9% of adhesive, 4% of filler, 0.8% of essence, 1.5% of glidant and 0.8% of lubricant.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 40% of soybean lecithin, 1% of vitamin E, 2% of royal jelly powder, 3% of carob extract, 28% of sweetener, 15% of moisture-proof agent, 6% of adhesive, 3% of filler, 0.5% of essence, 1% of glidant and 0.5% of lubricant.
In some possible implementations, the tablet comprises the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 25% of soybean lecithin, 4% of vitamin E, 8% of royal jelly powder, 8% of carob extract, 20% of sweetener, 12% of moisture-proof agent, 12.3% of adhesive, 6% of filler, 1.5% of essence, 2% of glidant and 1.2% of lubricant.
The effects of the foregoing embodiments of the present application are discussed in detail in the foregoing, and are not repeated here.
In some possible implementations, in the step S20, the step of mixing and granulating includes: wet granulating sweetener, dampproof agent, binder and water, inducing binder viscosity by wet granulation, and making the dampproof agent, sweetener and binder into granule. Drying, sieving, mixing with soybean lecithin, vitamin E, lac Regis Apis powder, carob bean extract, filler, essence, glidant and lubricant, and granulating to obtain soybean lecithin granule with blood lipid reducing effect. Then the soybean lecithin tablet with the blood fat reducing function is prepared by tabletting.
In some possible implementations, the mass ratio of the total mass of sweetener, moisture barrier, and binder to water is 1: (0.2-0.3). The embodiment of the application adopts purified water to induce the viscosity of the adhesive, and fully ensures that the sweetener, the moisture-proof agent and the adhesive form uniformly mixed particles by a wet granulation method. Wherein, the material viscosity induced by the small amount of purified water is insufficient, the granularity is poor, and the powder is more; the material viscosity is too high when the purified water is used in a large amount, the particles are relatively wet and hard, and the particles are not easy to screen, so that the taste of the tablet is affected. In some embodiments, the mass ratio of the total mass of sweetener, moisture barrier, and binder to water may be 1: (0.2-0.25), 1: (0.25 to 0.3), and the like.
In some possible implementations, the step of drying and sieving includes: drying the wet granulated particles at 50-65 ℃ until the moisture content in the particles is not higher than 2.5wt%, reducing the water content, avoiding the moisture from interfering with the stabilization of the soybean lecithin tablet with the blood lipid reducing function, and then sieving the soybean lecithin tablet with the 20-mesh sieve to obtain the soybean lecithin particles with small particle size and high uniformity and the blood lipid reducing function.
In some possible implementations, after the raw material components are obtained, a treatment step of passing soybean lecithin through a 20-mesh sieve and passing other raw material components through a 40-mesh sieve is further included. The raw material components are respectively screened to obtain the raw material components with small particle size and uniform particle size, so that the raw material components are uniformly mixed in the subsequent granulation process, and the prepared soybean lecithin tablet with the functions of reducing blood fat, which has the advantages of accurate tablet dosage, uniform main medicine content, stable quality, small volume and compactness, is less influenced by factors such as external air, light rays and moisture, and is not easy to deteriorate.
In some possible implementation modes, the prepared soybean lecithin tablet with the blood lipid reducing function is a chewable tablet, and each tablet weighs 0.8 g-1.5 g, and is orally taken and swallowed after being chewed when being used. The soybean lecithin chewable tablet with the blood lipid reducing function is convenient to carry and simple to use, and has the effects of reducing blood lipid, preventing cardiovascular and cerebrovascular diseases and the like.
In order to make the implementation details and operation of the present application clearly understood by those skilled in the art, and to significantly embody the improved performance of the soybean lecithin with the blood lipid reducing function and the preparation method thereof according to the embodiments of the present application, the above technical solution is illustrated by the following examples.
Example 1
A soybean lecithin chewable tablet with blood lipid reducing function comprises the following components: 30% of soybean lecithin, 3% of vitamin E, 5% of royal jelly powder, 3% of carob bean extract, 24% of anhydrous dextrose, 16% of tricalcium phosphate, 10% of corn starch, 5% of isolated soybean protein, 1% of walnut powder essence, 2% of silicon dioxide and 1% of magnesium stearate.
The preparation process comprises the following steps:
(1) weighing: weighing the raw materials and the auxiliary materials according to the formula amount for standby;
(2) pretreatment of raw materials and auxiliary materials: sieving soybean lecithin with 20 mesh sieve, and sieving the rest materials with 40 mesh sieve;
(3) granulating: mixing sweetener, dampproof agent and adhesive, placing into wet granulating machine, adding purified water for wet granulating;
(4) and (3) drying: drying the prepared particles at 65 ℃ and controlling the water content to be less than or equal to 2.5%, and sieving the particles with a 20-mesh sieve for later use;
(5) mixing: adding soybean lecithin, vitamin E, lac Regis Apis powder, carob bean extract, filler, essence, glidant and lubricant into the granule, and mixing;
(6) Tabletting: the weight of the tablet is 1.0 g/tablet;
(7) and (5) packaging.
Example 2
A soybean lecithin chewable tablet with blood lipid reducing function comprises the following components: 20% of soybean lecithin, 2% of vitamin E, 4% of royal jelly powder, 5% of carob extract, 30% of anhydrous dextrose, 20% of tricalcium phosphate, 11.9% of corn starch, 4% of soybean protein isolate, 0.8% of walnut powder essence, 1.5% of silicon dioxide and 0.8% of magnesium stearate.
The preparation process comprises the following steps:
(1) weighing: weighing the raw materials and the auxiliary materials according to the formula amount for standby;
(2) pretreatment of raw materials and auxiliary materials: sieving soybean lecithin with 20 mesh sieve, and sieving the rest materials with 40 mesh sieve;
(3) granulating: mixing sweetener, dampproof agent and adhesive, placing into wet granulating machine, adding purified water for wet granulating;
(4) and (3) drying: drying the prepared particles at 50-65 ℃ to control the water content to be less than or equal to 2.5%, and sieving the particles with a 20-mesh sieve for later use;
(5) mixing: adding soybean lecithin, vitamin E, lac Regis Apis powder, carob bean extract, filler, essence, glidant and lubricant into the granule, and mixing;
(6) tabletting: the weight of the tablet is 1.5 g/tablet;
(7) and (5) packaging.
Example 3
A soybean lecithin chewable tablet with blood lipid reducing function is prepared by: 40% of soybean lecithin, 1% of vitamin E, 2% of royal jelly powder, 3% of carob extract, 28% of anhydrous dextrose, 15% of tricalcium phosphate, 6% of corn starch, 3% of isolated soybean protein, 0.5% of walnut powder essence, 1% of silicon dioxide and 0.5% of magnesium stearate.
The preparation process comprises the following steps:
(1) weighing: weighing the raw materials and the auxiliary materials according to the formula amount for standby;
(2) pretreatment of raw materials and auxiliary materials: sieving soybean lecithin with 20 mesh sieve, and sieving the rest materials with 40 mesh sieve;
(3) granulating: mixing sweetener, dampproof agent and adhesive, placing into wet granulating machine, adding purified water for wet granulating;
(4) and (3) drying: drying the prepared particles at 50-65 ℃ to control the water content to be less than or equal to 2.5%, and sieving the particles with a 20-mesh sieve for later use;
(5) mixing: adding soybean lecithin, vitamin E, lac Regis Apis powder, carob bean extract, filler, essence, glidant and lubricant into the granule, and mixing;
(6) tabletting: the weight of the tablet is 0.8 g/tablet;
(7) and (5) packaging.
Example 4
A soybean lecithin chewable tablet with blood lipid reducing function is prepared by: 25% of soybean lecithin, 4% of vitamin E, 8% of royal jelly powder, 8% of carob extract, 20% of anhydrous dextrose, 12% of tricalcium phosphate, 12.3% of corn starch, 6% of soybean protein isolate, 1.5% of walnut powder essence, 2% of silicon dioxide and 1.2% of magnesium stearate.
The preparation process comprises the following steps:
(1) weighing: weighing the raw materials and the auxiliary materials according to the formula amount for standby;
(2) Pretreatment of raw materials and auxiliary materials: sieving soybean lecithin with 20 mesh sieve, and sieving the rest materials with 40 mesh sieve;
(3) granulating: mixing sweetener, dampproof agent and adhesive, placing into wet granulating machine, adding purified water for wet granulating;
(4) and (3) drying: drying the prepared particles at 50-65 ℃ to control the water content to be less than or equal to 2.5%, and sieving the particles with a 20-mesh sieve for later use;
(5) mixing: adding soybean lecithin, vitamin E, lac Regis Apis powder, carob bean extract, filler, essence, glidant and lubricant into the granule, and mixing;
(6) tabletting: the weight of the tablet is 1.2 g/tablet;
(7) and (5) packaging.
Example 5
The formulation of example 1 was used with the difference that: removing anhydrous glucose in the formula, keeping the proportion of other components unchanged, keeping the weight of tablet at 1.0 g/tablet unchanged, and tabletting.
Example 6
The formulation of example 1 was used with the difference that: removing tricalcium phosphate in the formula, keeping other components in unchanged proportion, keeping the weight of tablet at 1.0 g/tablet unchanged, and tabletting.
Example 7
The formulation of example 1 was used with the difference that: and (3) the granulating process is to change the water for inducing the adhesive into 4% hydroxypropyl methyl cellulose solution for granulating, and the other steps are unchanged, the weight of the tablet is kept unchanged at 1.0 g/tablet, and the tablet is pressed.
Further, in order to verify the progress of the embodiments of the present application, the following performance tests were performed on the above-described embodiments, respectively.
1. The soybean lecithin chewable tablets with the blood lipid reducing function prepared in examples 1 to 4 were subjected to rat experiments. 60, 6 groups of 10 (male and female halves) each. The rats in the blank group were fed with normal feed, the control group was fed with high-fat feed, and the treatment group was fed with high-fat feed in combination with the soybean lecithin chewable tablets (crushed and mixed in feed at a rate of 2 g/kg) having the blood lipid-lowering function prepared in examples 1 to 4. The test period is 30 days, and the contents of Total Cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in the serum indexes of the rats are detected. The test results are shown in table 1 below:
table 1: rat serum index detection result (unit mmol/L)
| Detection index | TC | TG | LDL-C | HDL-C |
| Blank group | 1.61±0.14 | 1.18±0.13 | 0.65±0.07 | 0.75±0.10 |
| Control group | 1.84±0.18 | 1.69±0.15 | 0.78±0.08 | 0.61±0.09 |
| Treatment group-example 1 | 1.66±0.16 | 1.28±0.17 | 0.69±0.06 | 0.70±0.08 |
| Treatment group-example 2 | 1.73±0.13 | 1.36±0.18 | 0.72±0.08 | 0.68±0.09 |
| Treatment group-example 3 | 1.64±0.10 | 1.28±0.09 | 0.68±0.06 | 0.72±0.10 |
| Treatment group-example 4 | 1.69±0.15 | 1.30±0.16 | 0.70±0.07 | 0.70±0.07 |
As shown in the test results of the table 1, the soybean lecithin chewable tablets with the blood lipid reducing function prepared in the embodiments 1 to 4 can effectively reduce the TC, TG, LDL-C content in the serum of rats, increase the HDL-C content, and have the effects of reducing blood lipid, preventing cardiovascular and cerebrovascular diseases and the like.
2. Comparing example 1 with example 5, 10 persons were randomly selected for taste evaluation, and the results are shown in table 2 below:
table 2: taste evaluation results
| Detection index | Excellent (excellent) | Good grade (good) | In (a) | Poor quality | Difference of difference |
| Example 1 | 3 persons | 5 people | 2 persons | 0 person | 0 person |
| Example 5 | 0 person | 1 person | 2 persons | 5 people | 2 persons |
As is clear from the test results in Table 2, the addition of anhydrous dextrose as a sweetener in example 1 can mask the bitter and fishy smell of soybean lecithin, and the taste is remarkably improved.
3. Comparing example 1 with example 6, a 3 month stability test (40 ℃ + -2 ℃ C.; 75% + -5% RH) was performed in PE bottles, and the results are shown in Table 3 below:
table 3: stability test results
As can be seen from the test results in Table 3, the addition of tricalcium phosphate as a moisture-proof agent in example 1 can prevent the tablets from absorbing moisture during the storage process, increase the stability of the tablets and prolong the storage date.
4. Comparing example 1 with example 7, the results are shown in table 4 below, comparing the granule properties and the tablet mouthfeel:
table 4: experimental results
As is clear from the test results in Table 4, in example 7, the granules were granulated with purified water, the hardness of the granules was moderate, the granule size was uniform, and the taste of the tablets after tabletting was good.
The test results of the tests 2-4 show that the soybean lecithin tablet with the blood lipid reducing function simultaneously comprises the following raw material components in percentage by mass: 20 to 40 percent of soybean lecithin, 1 to 5 percent of vitamin E, 1 to 10 percent of royal jelly powder, 1 to 10 percent of carob bean extract, 20 to 40 percent of sweetener, 10 to 30 percent of moisture-proof agent, 5 to 20 percent of adhesive, 1 to 10 percent of filling agent, 0.5 to 1.5 percent of essence, 1 to 2 percent of glidant and 0.5 to 1.5 percent of lubricant, the tablet has better stability, is less susceptible to the influence of factors such as external air, light, moisture and the like, is not easy to deteriorate, and is convenient to transport, store and use.
The foregoing description of the preferred embodiments of the application is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the application.
Claims (10)
1. The soybean lecithin tablet with the blood lipid reducing function is characterized by comprising functional components and auxiliary materials, wherein the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob extract.
2. The soybean lecithin tablet with hypolipidemic function of claim 1, wherein the excipients include sweetener, moisture-proof agent, binder, filler, essence, glidant and lubricant.
3. The soybean lecithin tablet with the blood lipid reducing function according to claim 2, which is characterized by comprising the following raw material components in percentage by mass, based on 100% of the total mass of the tablet: 20-40% of soybean lecithin, 1-5% of vitamin E, 1-10% of royal jelly powder, 1-10% of carob bean extract, 20-40% of sweetener, 10-30% of moisture-proof agent, 5-20% of adhesive, 1-10% of filler, 0.5-1.5% of essence, 1-2% of glidant and 0.5-1.5% of lubricant.
4. A soy lecithin tablet having a hypolipidemic function according to claim 2 or 3, wherein the sweetener comprises at least one of anhydrous dextrose, sucrose, mannitol;
and/or, the moisture-proof agent comprises at least one of tricalcium phosphate and anhydrous calcium hydrogen phosphate;
and/or the binder comprises at least one of corn starch, modified starch, maltodextrin;
and/or the filler comprises at least one of soy protein isolate, soy flour, milk protein concentrate;
and/or the essence comprises at least one of walnut powder essence, almond essence and walnut essence;
and/or the glidant comprises at least one of silicon dioxide, micro silica gel and polyethylene glycol;
and/or the lubricant comprises at least one of magnesium stearate, stearic acid and talcum powder.
5. The soybean lecithin tablet with the blood lipid reducing function as claimed in claim 4, wherein the tablet comprises the following raw material components in percentage by mass based on 100% of the total mass of the tablet: 30% of soybean lecithin, 3% of vitamin E, 5% of royal jelly powder, 3% of carob extract, 24% of sweetener, 16% of moisture-proof agent, 10% of adhesive, 5% of filler, 1% of essence, 2% of glidant and 1% of lubricant;
Or 20% of soybean lecithin, 2% of vitamin E, 4% of royal jelly powder, 5% of carob extract, 30% of sweetener, 20% of moisture-proof agent, 11.9% of adhesive, 4% of filler, 0.8% of essence, 1.5% of glidant and 0.8% of lubricant;
alternatively, 40% of soybean lecithin, 1% of vitamin E, 2% of royal jelly powder, 3% of carob extract, 28% of sweetener, 15% of moisture-proof agent, 6% of adhesive, 3% of filler, 0.5% of essence, 1% of glidant and 0.5% of lubricant;
alternatively, soybean lecithin 25%, vitamin E4%, royal jelly powder 8%, carob extract 8%, sweetener 20%, moisture-proof agent 12%, binder 12.3%, filler 6%, essence 1.5%, glidant 2% and lubricant 1.2%.
6. The soybean lecithin tablet with blood lipid-lowering function as claimed in any one of claims 1 to 3 or 5, wherein the soybean lecithin tablet with blood lipid-lowering function comprises soybean lecithin chewable tablets with blood lipid-lowering function, each tablet weighing 0.8g to 1.5g.
7. The preparation method of the soybean lecithin tablet with the blood lipid reducing function is characterized by comprising the following steps:
obtaining raw material components, wherein the raw material components comprise functional components and auxiliary materials, and the functional components comprise soybean lecithin, vitamin E, royal jelly powder and carob bean extract;
And mixing the raw material components, granulating, and tabletting to obtain the soybean lecithin tablet with the blood lipid reducing function.
8. The preparation method of the soybean lecithin tablet with the blood lipid reducing function as claimed in claim 7, wherein the total mass of the raw material components is 100%, and the soybean lecithin tablet comprises the following components in percentage by mass: 20-40% of soybean lecithin, 1-5% of vitamin E, 1-10% of royal jelly powder, 1-10% of carob bean extract, 20-40% of sweetener, 10-30% of moisture-proof agent, 5-20% of adhesive, 1-10% of filler, 0.5-1.5% of essence, 1-2% of glidant and 0.5-1.5% of lubricant.
9. The method for preparing a soybean lecithin tablet having a hypolipidemic function according to claim 8, wherein the step of mixing granulation comprises: wet granulating the sweetener, the moisture-proof agent and the adhesive with water according to the formula amount, drying, sieving, and mixing with the soybean lecithin, the vitamin E, the royal jelly powder, the carob bean extract, the filler, the essence, the glidant and the lubricant according to the formula amount for granulation.
10. The method for preparing a soybean lecithin tablet having a hypolipidemic function according to claim 9, wherein the mass ratio of the total mass of the sweetener, the moisture-proof agent and the binder to the water is 1: (0.2-0.3);
and/or, the step of drying and sieving comprises: drying the wet granulated particles at 50-65 ℃ until the moisture content in the particles is not higher than 2.5wt%, and sieving the particles with a 20-mesh sieve;
and/or, after the raw material components are obtained, the method further comprises the treatment step of sieving the soybean lecithin with a 20-mesh sieve and sieving other raw material components with a 40-mesh sieve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310889789.XA CN117016786A (en) | 2023-07-19 | 2023-07-19 | Soybean lecithin tablet with blood lipid reducing function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310889789.XA CN117016786A (en) | 2023-07-19 | 2023-07-19 | Soybean lecithin tablet with blood lipid reducing function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117016786A true CN117016786A (en) | 2023-11-10 |
Family
ID=88628929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310889789.XA Pending CN117016786A (en) | 2023-07-19 | 2023-07-19 | Soybean lecithin tablet with blood lipid reducing function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117016786A (en) |
-
2023
- 2023-07-19 CN CN202310889789.XA patent/CN117016786A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018145664A1 (en) | Anti-fatigue composition for use in improving endurance performance | |
| CN104274509B (en) | Healthy product composition containing cordyceps sinensis and eucommia Bark male flower and its preparation method and application | |
| JP2010521420A (en) | Use of guanidinoacetic acid (salt) in combination with betaine and / or choline for the manufacture of health enhancers | |
| WO2018103729A1 (en) | Use of chlorogenic acid in preparation of drugs or health-care products for stimulating appetite | |
| TWI719691B (en) | Use of lactobacillus reuteri gkr1 for preparing composition of reducing uric acid | |
| JP2001187736A (en) | Nutritive analeptic and nutritive analeptic drink | |
| CN103735556B (en) | A kind of multi-vitamin mineral composite effervescent sheet and preparation method | |
| JPH0920660A (en) | Stress-resistant composition | |
| EP3165221B1 (en) | Blood-fat reducing composition and application thereof | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN109965072A (en) | A kind of pressed candy and the preparation method and application thereof conserving liver | |
| CN117016786A (en) | Soybean lecithin tablet with blood lipid reducing function and preparation method thereof | |
| CN110384240A (en) | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application | |
| CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
| KR20230145464A (en) | Drug composition for treating hyperlipidemia and method for producing the same | |
| WO2022155314A1 (en) | Mushroom blend for increasing butyrate production in the gut biome | |
| CN102579956A (en) | Medicament composition and application thereof | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method | |
| CN106387915B (en) | Qi and coffee vigor-benefiting effervescent tablet and preparation process and application thereof | |
| CN104435003A (en) | Cordyceps militaris health product preparation and preparation method thereof | |
| JP2001048794A (en) | Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm | |
| CN112493487B (en) | Composition for enhancing human immunity, preparation method thereof and health-care product | |
| CN115721614B (en) | alpha-KG sustained release preparation and application thereof | |
| WO2022161485A1 (en) | Composition comprising n-acetylglucosamine, preparation method for same, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |